04:43,18,May,2011 | (206/0/0) | Original

clindamycin bacterial vaginosis


0 replied "very tiger," You know what? I caught today to answer 10 . 0 can cure infertility it? Suffers with it? 0 answers What was diagnosed with 2 degrees of cervical erosion and how treatment of pelvic fluid I have not given birth to a child to answer Can I also . 0 age from 17 to 25 years of age by pain or pain when the time is what ails you ? No treatment will lead . a woman have a baby if the answer to the hospital, where cesarean section was cut production ah? 0 5 it will answer pregnant? 0 answers Appendix shows the left uterine size 16x13mm of a cystic that be? 1 answer confinement ear accidentally discovered a packet of baby grew up a little touch now will not live .
clindamycin bacterial vaginosis

Half of clindamycin phosphate for the synthesis of antibiotics, is a derivative of lincomycin, the treatment of bacterial vaginosis cure rate is high and the short duration of only three days, than other drugs such as oral metronidazole or clindamycin shorter course of treatment doubled, and the vaginal administration can improve efficacy, reduce side effects, than oral or injected systemic administration of a lower incidence of adverse reactions, effervescent tablets more convenient to use, fast onset and so on. 【Uses】 for the treatment of bacterial vaginosis. 【Specification】 0.1g, are three new drugs. Drug name】 Common name: English name of the clindamycin phosphate: Clindamycin Phosphate Vaginal Effervescent Tablets Pinyin: Kelinmeisu Linsuanzhi Yindao Paotengpian 【Specification】 【Price】 0.1g yet available * 【Approval number】 【Zhunzi H20061182 production enterprises in Hainan Chang'an International Pharmaceutical Co., Ltd.】 【Indication】 / Indications for the treatment of bacterial vaginosis. Dosage vagina once a day, before going to sleep at night after washing the vulva, the goods will 0.1g (1 piece) into the vagina at the posterior fornix for 7 days. Or doctor. Adverse reactions 1. Foreign clinical studies have reported, 589 patients with clindamycin phosphate suppositories, adverse reaction rate was 10.5%, of which 3 patients (0.5%) discontinued treatment. Adverse reactions include: urinary and reproductive system: disorder (3.4%), vaginal pain (1.9%), candida vaginitis (1.5%). Systemic effects: fungal infection (1.0%) incidence of <1% of adverse reactions: Urogenital system: Menstrual disorder, dysuria. Body: abdominal cramps, abdominal pain, fever, Association abdominal pain, headache. Digestive System: diarrhea, vomiting and nausea. Skin: Non-medicinal parts of the skin redness, rash, medication pain, dermatitis. 2. The domestic situation in clinical studies adverse reaction rate of the product of 4.23% (3 / 72). Adverse effects included mild to moderate vaginal irritation, palpitation, vomiting, chills, vaginal bleeding
, symptoms disappeared after stopping. A transient may also appear mildly elevated serum transaminases. Taboo 1. To clindamycin, lincomycin, or other components of the product history of allergy were banned. 2. Have limitations enteritis, ulcerative colitis, or antibiotic-associated colitis patients with a history of disabled. 【Notice】 1. This product is for vaginal administration, should not oral. 2. Menstrual period the patient should not be using this product can be used after a clean period. 3. In making the FDA should be avoided during sexual intercourse, and avoid douching. 4. There withdrawal allergic reaction when a doctor. 5. Such as the use of excessive or severe adverse reactions, seek medical attention. Change the characteristics of the product prohibited. 7. Keep out of reach of children. 8. If are using other drugs before using this product should consult a doctor or pharmacist. Pregnant women and lactating women drug】 1. Pregnant women should weigh the interests decide whether the FDA is generally not used. 2. Lactating women subject the FDA, breast-feeding should be suspended. Old drug】 【clinical cases is not enough proof of vaginal preparations of clindamycin phosphate in the elderly and the young age of 65 whether there are differences between
Clindamycin phosphate vaginal tablets
Main components of the Prescription clindamycin phosphate,
With clindamycin 100mg / piece of the original four new drugs - shaped tablets.

Topical treatment of gynecological product market positioning of bacterial vaginosis antibiotics
Clindamycin phosphate chemical semi-synthetic derivative clindamycin, clindamycin precursor for the drug into the body of its rapid hydrolysis of clindamycin and show their pharmacological activity, antibacterial spectrum and Franklin mildew factors the same, but good fat-soluble and permeable Bike Lin adriamycin, absorbed quickly, lasting effect. There are currently clindamycin hydrochloride and clindamycin phosphate market, and has entered the multi-national pharmacopoeia. Clindamycin phosphate ester solubility and permeability in the superior hydrochloride, and its local irritation also decreased significantly. Narrow antibacterial spectrum of clindamycin on the aerobic Gram-negative largely ineffective, but Gram-positive aerobes good effect, especially effective on anaerobic bacteria with broad-spectrum antimicrobial activity, efficacy than the forest can be ADM strong 4 to 8 times. It is good because of its antibacterial activity against anaerobes and the smaller local irritation, bacterial vaginosis in the local treatment has obvious advantages.
National data show that bacterial vaginosis accounts for the vulva, vaginal infections, 40-50%, which is a vaginal infection sexually transmitted disease in the highest, far more than the vaginal trichomoniasis and fungal infection, even conservative estimates, our patients have bacterial vaginosis up to tens of millions. Epidemiological survey of foreign study, bacterial vaginosis accounted for 34.5% of patients with gynecological clinic, gynecological infectious diseases accounted for 70% in the diagnosis of sexually transmitted disease patients, 61% of patients associat
ed with bacterial vaginosis.
Since 1989 the U.S. FDA has approved clindamycin phosphate market, there have been solutions, creams, gels, vaginal suppositories, and other agents listed. August 1999,       strong company to obtain FDA approval of clindamycin phosphate market, has become the treatment of bacterial vaginosis in one of the drugs of choice.
Competition gynecological vaginal preparations currently used most effectively a variety of bacteria, clindamycin vaginal tablets specifically for bacterial vaginosis and effective. Foreign clinical study data showed that the cure rate of clindamycin vaginal suppository up to 92%, drug-related adverse events was significantly lower than that of metronidazole. Metronidazole effervescent tablets in March 2003 ordering the national retail market selling variety, the eighth in the gynecological products.
Features listed abroad in the course of vaginal suppositories produce substrates outflow, overcast
Add a comment
  • Nickname [Register]
  • Password Optional
  • Site URI
  • Email
Enable HTML Enable UBB Enable Emots Hidden Remember